Global High-density Multiplexed Diagnostic Assays Market to Reach $3.2 Billion by 2027
Amid the COVID-19 crisis, the global market for High-density Multiplexed Diagnostic Assays estimated at US$1.2 Billion in the year 2020, is projected to reach a revised size of US$3.2 Billion by 2027, growing at aCAGR of 14.4% over the period 2020-2027. High-Density Multiplexed Diagnostic Assays (500-10,000 plex), one of the segments analyzed in the report, is projected to record 14.1% CAGR and reach US$1.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) segment is readjusted to a revised 14.9% CAGR for the next 7-year period.
The U.S. Market is Estimated at $363.6 Million, While China is Forecast to Grow at 13.9% CAGR
The High-density Multiplexed Diagnostic Assays market in the U.S. is estimated at US$363.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$551.1 Million by the year 2027 trailing a CAGR of 13.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.8% and 12.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.We bring years of research experience to this 6th edition of our report. The 175-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.Competitors identified in this market include, among others,
- Abbott Laboratories
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Erba Diagnostics, Inc.
- F. Hoffmann-La Roche AG
- Gold Standard Diagnostics Corporation
- Hologic, Inc.
- Luminex Corporation
- Randox Laboratories Ltd.
- Thermo Fisher Scientific, Inc.